Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

chikungunya virus antigen, recombinant Senegal strain 37997 · Vimkunya

Vaccine · Immune activation, directed at chikungunya virus antigen (Senegal strain 37997) · developed by Bavarian Nordic

Approved FDA, Feb 2025
1 Registered trials

What is chikungunya virus antigen, recombinant Senegal strain 37997?

VIMKUNYA is a recombinant chikungunya vaccine based on the Senegal strain 37997 of chikungunya virus antigen. It is studied in chikungunya virus infection and chikungunya fever.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vimkunya, VIMKUNYA
Drug type
Vaccine
Targets
chikungunya virus antigen (Senegal strain 37997) (antigen)
Mechanism
Immune activation, directed at chikungunya virus antigen (Senegal strain 37997)
Therapy area
Infectious disease
Developer
Bavarian Nordic A/S
In trials of
VALN
FDA status
Approved as Vimkunya (February 14, 2025), BLA125820

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06928753 Phase 4 Chikungunya Virus Infection Recruiting VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chikungunya Virus Infection

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.